Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.61 |
| ▸ | FNTB | P49356 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992570 | 1.00 | FNTA (0.61) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL21243060 | 1.00 | FNTA (0.61) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL8752386 | 1.00 | FNTA (0.61) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| Acetic Acid SCHEMBL2582613 | 0.99 | FNTA (0.60) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL12156704 | 0.91 | FNTA (0.59) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL25784983 | 0.91 | FNTA (0.51) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL22038641 | 0.91 | FNTA (0.51) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL10394983 | 0.89 | FNTA (0.49) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL9069884 | 0.88 | NFKB1 (0.58) | FNTAFNTBLMNASMN1; SMN2NFKB1 | |
| SCHEMBL9073533 | 0.87 | FNTA (0.51) | FNTAFNTBLMNASMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4436583-A1 | TREATMENT OF NF-kB-MEDIATED DISEASE | ReveraGen BioPharma, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20240299416-A1 | TREATMENT OF NF-kB-MEDIATED DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20240285650-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20240226117-A1 | TREATMENT OF CONGENITAL ADRENAL HYPOPLASIA | REVERAGEN BIOPHARMA, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226117-A1 | TREATMENT OF CONGENITAL ADRENAL HYPOPLASIA | REVERAGEN BIOPHARMA, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226117-A1 | TREATMENT OF CONGENITAL ADRENAL HYPOPLASIA | REVERAGEN BIOPHARMA, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240139210-A1 | TREATMENT OF NF-KB-MEDIATED DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-2444092-A1 | Non-hormonal steroid modulators of nf-kb for treatment of disease | Validus Biopharma, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2012-04-19 | — | — | US | disclosed |
| US-8049021-B2 | Fluorination; catalytic acetylation | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-11-01 | — | — | US | disclosed |
| WO-2011127048-A2 | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | VALIDUS GENETICS (US) | 2010-04-08 | — | — | US | disclosed |
| US-20080234506-A1 | PROCESS FOR THE PREPARATION OF FLUOROTETRAENE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226117-A1 | TREATMENT OF CONGENITAL ADRENAL HYPOPLASIA | CYP21A2, HSD17B2, NR3C2 | FNTA 1026/4885FNTB 2694/4885LMNA 3187/4885 |
| US-20080234506-A1 | PROCESS FOR THE PREPARATION OF FLUOROTETRAENE | CYP17A1, CYP21A2, CYP19A1 | FNTA 139/4885FNTB 158/4885LMNA 2820/4885 |
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | FNTA 323/4885FNTB 341/4885LMNA 2288/4885 |
| US-20240285650-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | FNTA 2077/4885FNTB 1122/4885LMNA 671/4885 |
| US-20240299416-A1 | TREATMENT OF NF-kB-MEDIATED DISEASE | NFKB2, NFKB1, NFKBIA | FNTA 2556/4885FNTB 2659/4885LMNA 28/4885 |
| US-20120094970-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | FNTA 2077/4885FNTB 1122/4885LMNA 671/4885 |
| US-20100087408-A1 | NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | FNTA 2077/4885FNTB 1122/4885LMNA 671/4885 |
| US-20240139210-A1 | TREATMENT OF NF-KB-MEDIATED DISEASE | NFKB2, NFKB1, NFKBIA | FNTA 2556/4885FNTB 2659/4885LMNA 28/4885 |
| US-11833159-B2 | Non-hormonal steroid modulators of NF-kB for treatment of disease | NFKBIA, NFKB2, NFKB1 | FNTA 2077/4885FNTB 1122/4885LMNA 671/4885 |
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | FNTA 323/4885FNTB 341/4885LMNA 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.